Thymidylate synthase: A target for combination therapy and determinant of chemotherapeutic response in colorectal cancer

Oncology

Volumn 57, Issue 3, 1999, Pages 179-194

  Van Triest, B ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 Fluorouracil; Antifolates; Irinotecan; Oxaliplatin; Thymidylate synthase; Topoisomerase

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; 2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; FLUOROPYRIMIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEMCITABINE; NOLATREXED; OXALIPLATIN; PEMETREXED; RALTITREXED; THYMIDINE PHOSPHATE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CHEMICAL STRUCTURE; COLORECTAL CANCER; DIARRHEA; DNA SYNTHESIS; DRUG ACCUMULATION; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TRANSPORT; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; NEPHROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FOLIC ACID ANTAGONISTS; HUMANS; THYMIDYLATE SYNTHASE;

EID: 0032868050     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012030     Document Type: Review

References (125)

1. Radparvar S, Houghton PJ, Houghton JA: Characteristics of thymidylate synthase purified from a human colon adenocarcinoma. Arch Biochem Biophys 1988;260:342-350.
2. Eriksson S, Arner E, Spaskokoukotskaja T, Wang L, Karlsson A, Brosjo C, Gunven P, Julusson G, Liliemark J: Properties and levels of deoxy-nucleoside kinases in normal and tumor cells: Implications for chemotherapy. Adv Enzyme Regul 1994;34:13-25.
3. Lockshin A, Mondal K, Danenberg PV: Spectroscopic studies of ternary complexes of thymidylate synthetase, deoxyribonucleotides, and folate analogs. J Biol Chem 1984;259: 11346-11352.
4. Washtein WL: Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil. Mol Pharmacol 1984;25:171-177.
5. Van der Wilt CL, Pinedo HM, Smid K, Peters GJ: Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 1992;52:2017-2024.
6. Keyomarsi K, Samet J, Molnar G, Pardee AB: The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J Biol Chem 1993;268:15142-15149.
7. Chu E, Zinn S, Boarman D, Allegra CJ: Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 1990;50:5834-5840.
8. Chu E, Voeller DM, Johnston PG, Zinn S, Allegra CJ: Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol 1993;43:527-533.
9. Chu E, Voeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S, Allegra CJ: Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 1990;90: 517-521.
10. Chu E, Voeller DM, Morrison PF, Jones KL, Takechi T, Maley GF, Maley F, Allegra CJ: The effect of reducing reagents on binding of thymidylate synthase protein to thymidylate synthase messenger RNA. J Biol Chem 1994; 269;20289-20293.
11. Chu E, Allegra CJ: The role of thymidylate synthase as an RNA binding protein. Bioessays 1996;18:191-198.
12. Chu E, Takechi T, Jones KL, Voeller DM, Copur SM, Maley GF, Maley F, Segal S, Allegra CJ: Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro. Mol Cell Biol 1995;15:179-185.
13. Chu E, Copur S, Jones KL, Khleif S, Voeller D, Maley GF, Maley F, Allegra CJ: Thymidylate synthase regulates the translation of p53 mRNA. Proc Am Assoc Cancer Res 1995;36: 3355.
14. Li W, Fan J, Hochhauser D, Banerjee D, Zielinski Z, Almasa A, Yin Y, Kelly R, Wahl GM, Bertino JR: Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 1995;92:10436-10440.
15. Van Laar JAM, Van Groeningen CJ, Ackland SP, Rustum YM, Peters GJ: Comparison of 5-fluoro-2′-deoxyuridine to 5-fluorouracil, and their role in the treatment of advanced colorectal cancer. Eur J Cancer 1998;34:296-306.
16. Mandel HG: The target cell determinants of the antitumor actions of 5FU: Does FU incorporation into RNA play a role. Cancer Treat Rep 1981;65:63-71.
17. Goshal K, Jacob ST: Specific inhibition of preribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res 1994;54:632-636.
18. Wurzer JC, Tallarida RJ, Sirover MA: New mechanism of action of the cancer chemotherapeutic agent 5-fluorouracil in human cells. J Pharmacol Exp Ther 1994;269:39-43.
19. Peters GJ, Jansen G: Resistance to antimetabolites; in Schilsky RL, Milano GA, Ratain MJ (eds): Principles of Antineoplastic Drug Development and Pharmacology. New York, Dekker, 1996, chap 28, pp 543-585.
20. Arbuck SG: Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989;6:1036-1047.
21. Peters GJ, Van Groeningen CJ: Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 1991;2:469-480.
22. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7: 1407-1418.
23. Petrelli N, Douglass HO, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7: 1419-1426.
24. Piedbois P, Buyse M, Rustum Y, et al: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. By the advanced colorectal cancer meta-analysis project. J Clin Oncol 1992;10:896-903.
25. Meta-Analysis Group: Efficacy of intravenous continuous infusion of 5-fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-309.
26. Jackman AL, Calvert AH: Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 1995;6:871-881.
27. Peters GJ, Ackland SP: New antimetabolites in preclinical and clinical development. Exp Opin Invest Drugs 1996;5:637-679.
28. Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin M-B, Wilke H, Seeber S: Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors. J Clin Oncol 1997;15:389-400.
29. 10-propargyl-5,8-dideazafolic acid (CB3717). NCI Monogr 1987;5:213-218.
30. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitorthat is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res 1991;51:5579-5586.
31. Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, et al: Tomudex (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. Eur J Cancer 1995;31A:1945-1954.
32. Zalcberg JR, Cunningham D, Van Cutsem E, Francois E, Schornagel J, Adenis A, Green M, Iveson A, Azab M, Seymour I: ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J Clin Oncol 1996;14:716-721.
33. Harper P: Advanced colorectal cancer (ACC): Results from the latest raltitrexed Tomudex® (raltitrexed) comparative study. Proc Am Assoc Clin Oncol 1997;16:802.
34. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, Van Hazel G, Kerr D, Possinger K, Hietschold SM: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1998;16:2943-2952.
35. Zalcberg J: Overview of the tolerability of 'Tomudex' (raltitrexed): Collective clinical experience in advanced colorectal cancer. Anticancer Drugs 1997;8(suppl2):S17-S22.
36. Kerr DJ: Clinical efficacy of Tomudex' (raltitrexed) in advanced colorectal cancer. Anticancer Drugs 1997;8(suppl 2):S11-S15.
37. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, Hynes JB, Boyle FT, Peters GJ, Pinedo HM, Jansen G: Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: Correlates of molecular structure and biological activity. Mol Pharmacol 1995;48: 459-471.
38. Hanlon MH, Ferone R: In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase. Cancer Res 1996;56:3301-3306.
39. Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith M, Wardleworth JM, Boyle FT: The cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water-soluble, non-polyglutamatable quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 1997;3: 911-921.
40. Shih C, Chen VJ, Gossett LS, Gates SB, Mac-Kellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewey JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM: LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123.
41. Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckhardt JR, Rodriquez G, Corso SW, Fields SM, Langley C: Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995;13:2842-2850.
42. Cripps MC, Burnell M, Jolivet J, et al: Phase II study of a multi-targeted antifolate (LY231514) (MTA) as first-line therapy in patients with locally advanced or metastatic colorectal cancer (MCC). Proc Am Assoc Clin Oncol 1997;16:949.
43. Rafi I, Taylor GA, Calvete JA, Boddy AV, Balmanno K, Bailey N, Lind M, Calvert AH, Webber S, Jackson RC, Johnston A, Clendeninn N, Newell DR: Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridolthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion. Clin Cancer Res 1995;1:1275-1284.
44. Belani CP, Lembersky B, Ramanathan R, Cohn A, Loh K, Miller W, Green M, Chew R, Johnston A, Clendeninn N: A phase II trial of Thymitaq™ (AG337) in patients with adenocarcinoma of the colon. Proc Am Assoc Clin Oncol 1997;16:965.
45. Clarke SM, Boyer M, Millward M, Findlay M, Ackland S, Childs A, Brew S, Walcher V, Watt D, Campbell L: Phase II study of LY231514 in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Assoc Cancer Res 1997;38:1670.
46. Clendeninn NJ, Collier MA, Johnston AL, Loh KK, Cohn A, Kelly K, Glode LM, Stuart KE, Belani CP: Thymitaq™ (AG337): A novel thymidylate synthase inhibitor with clinical activity in solid tumors. Proc Am Assoc Cancer Res 1996;37:1176.
47. Rafi I, Calvert AH, Clendeninn N, Johnstone A, Hines J, Green M, Lind MJ, Bailey NP, Newell DR, Taylor GA, Calvette JA, Boddy AV: Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors. J Clin Oncol 1998;16:1131-1141.
48. John W, Picus J, Blanke C, Clark J, Schulman L, Rowinsky E, Thornton D, Loeher PJ: Activity of MTA (LY231514) in patients with advanced colorectal cancer - Results from a phase II study. Proc Am Assoc Clin Oncol 1998;17:1067.
49. Burris HA, Kisor DF, Smetzer JR, et al: A phase I pharmacokinetic (PK) study of the thymidylate synthase inhibitors 1843U89 during a daily × 5 bolus administration schedule. Proc ASCO 1996;15:477.
50. Rees C, Beale P, Mitchell F, Jackman A, Smith R, Mayne K, Hutchison M, Judson I: Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase (TS) inhibitor given as a five day continuous infusion. Ann Oncol 1998; 9(suppl2):609.
51. Ratain MJ, Goh BC, Smith R, Berucci D, Mani S, Vogelzang NJ, Schilsky RL, Hutchison M, Douglass E: Phase I study of ZD9331 using a 5-day short infusion schedule. Ann Oncol I998;9(suppl2):616.
52. Clendeninn NJ, Peterkin JJ, Webber S: AG331, a 'non-classical' lipophilic thymidylate synthase inhibitor for the treatment of solid tumors. Ann Oncol 1994;5(suppl 5):133.
53. Kelland LR, Kimbell R, Hardcastle A, Aherne GW, Jackman AL: Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines. Eur J Cancer 1995;31A:981-986.
54. Ackland S, Garg M, Van Moorsel CJA, Kuiper CM, Smid K., Peters GJ: Tomudex and cisplatin have additive cytotoxicity and no biochemical interaction in ovarian cancer cell lines. Ann Oncol 1998;9(suppl2):593.
55. Aschele C, Baldo C, Sobrero AF, Debernardis D, Bommann WG, Bertino JR: Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin Cancer Res 1998;4:1323-1330.
56. Kimbell R, Jackman AL: In vitro studies with ZD1694 (Tomudex™) and SN38 in human colon tumour cell lines; in Pfleiderer W, Rokos H (eds): Chemistry and Biology of Pteridines and Folates 1997: Proc 11th International Symposium. Berlin, Blackwell Science, pp 249-252.
57. Matsui S, Endo W, Wrzosek C, Haridas K, Seetharamulu P, Hausheer F, Rustum Y: Highly synergistic cytocidal effects by a mechanism-based ZD1694/DNA topoisomerase I inhibitor sequential combination. Proc Am Assoc Clin Oncol 1998;17:783.
58. Longo GSA, Izzo J, Chang YM, Tong WP, Zielinski Z, Grolick R, Chou T-C, Bertino JR: Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity. Clin Cancer Res 1998;4:469-473.
59. Van der Wilt CL, Kuiper CM, Pinedo HM, Peters GJ: Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines; in Pfleiderer W, Rokos H (eds): Chemistry and Biology of Pteridines and Folates 1997: Proc 11th International Symposium. Berlin, Blackwell Science, pp 245-248.
60. Raymond E, Djelloul S, Buquet-Fagot C, Mester J, Gespach C: Synergy between the nonclassical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells. Anticancer Drugs 1996;7:752-757.
61. Guimaraes MA, Greco WR, Slocum HK, Huben RP, Rustum YM: The combined-action of ICI-D1694, 5-fluoro-2′-deoxyuridine and 5-fluorouracil in inhibiting the growth of a human renal cell carcinoma cell line (RPMI-SE) in vitro. Int J Oncol 1994;4:137-141.
62. Raymond E, Gespach C, Louvet C, Allain P, Cvitkovic E, Mester J, Djelloul S, Buquet-Fagot C: Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997;8:875-885.
63. Guichard S, Hennebelle I, Bugat R, Canal P: Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 1998;55:667-676.
64. Teicher BA, Alvarez E, Lu K, Menon K, Dempsey J, Scholtz R: MTA (LY231514) in combination treatment regimens using human tumor xenografts and AMT-6 murine mammary carcinoma. Ann Oncol 1998;9(suppl 2):586.
65. Peters GJ, Van Moorsel CJA, Veerman G, Guechev A, Vermorken JB: Synergism of gemcitabine (GEM) with etoposide (VP), mitomycin C (MMC) and LY231514 (LY). Proc Am Assoc Cancer Res 1997;38:2136.
66. Izzo J, Zielinski Z, Chang YM, Bertino JR: Molecular mechanisms of the synergistic sequential administration of D1694 (Tomudex) followed by FUra in colon carcinoma cells. Proc Am Assoc Cancer Res 1995;36:2272.
67. Van der Wilt CL, Pinedo HM, Kuiper CM, Smid K, Peters GJ: Biochemical basis for the combined antiproliferative effect of AG337 or ZD1694 and 5-fluorouracil. Proc Am Assoc Cancer Res 1995;36:2260.
68. Scanlon KJ, Kashani-Sabet M: Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proc Natl Acad Sci USA 1988;85: 650-653.
69. Scanlon KJ, Kashani-Sabet M, Miyachi H, Sowers LC, Rossi J: Molecular basis of cisplatin resistance in human carcinomas: Model systems and patients. Anticancer Res 1989;9: 1301-1312.
70. Johnston PG, Geoffrey F, Drake J, Voeller D, Grem JL, Allegra CJ: The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Eur J Cancer 1996;32: 2148-2154.
71. Peters GJ, Van der Wilt CL, Gyergyay F, Van Laar JAM, Treskes M, Van der Vijgh WJF, Pinedo HM: Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil in murine tumors and plasma. Int J Radiat Oncol Biol Phys 1992;22: 785-789.
72. Van der Wilt CL, Van Laar J, Gyergyay F, Smid K, Peters GJ: Biochemical modification of the toxicity and antitumour effect of 5-fluorouracil and cis-plalinum by WR-2721 (ethiofos) in mice. Eur J Cancer 1992;28A:2017-2024.
73. Fischel JL, Etienne MC, Formento P, Renee N, Milano G: Search for an optimal schedule combining fluorouracil (FU) and oxaliplatin (LOHP) - Experimental data. Proc Am Assoc Cancer Res 1998;39:1087.
74. Rothenberg M, Eckardt JR, Kuhn JG, Burris HAR, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-1135.
75. Rougier P, Bugat R, Douillard JY, Culine S, Sue E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Convoy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients treated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-260.
76. Mullany S, Svingen PA, Kaufman SH, Erlichman C: Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells - Elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 1998;42:391-399.
77. Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P: Sequence dependent activity of irinotecan-5FU combination in human colon cancer model HT-29 in vitro and in vivo. Int J Cancer 1997;73:729-734.
78. Grivicich I, Mans DRA, De Rocha AB, Dalla Costa HS, Schwartsmann G: The cytotoxicity of the irinotecan (CPT-11)-5-fluorouracil (5-FU) combination in human colon carcinoma cell lines is related to the sequence-dependent introduction of DNA lesions. Proc Am Assoc Cancer Res 1997;38:2133.
79. Cantwell BM, Harris AL: The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid. Br J Cancer 1988;58:189-190.
80. Schwartz GK, Kemeny N, Bertino J, Saltz L, Sugarman A, Kelsen DK, Tong W, Lowery C: Interim results of phase I trial suggests that 'Tomudex™' (raltritrexed) may act synergistically with (5-fluorouracil) 5-FU in patients with advanced colorectal cancer. Ann Oncol 1998; 9(suppl 2):607.
81. Harstrick A, Mayer S, Muller C, Hilger R, Dohmen D, Kreisel C, Vanhoefer U, Scheulen ME, Wilke H, Seeber S: Combination therapy with infusional 5-FU and 'Tomudex' for patients (PTS) with advanced colorectal cancer - A phase I study. Proc Am Assoc Clin Oncol 1998; 17:772.
82. Fizazi K, Baudin E, Furrié P, Ducreux M, Soria JC, Le Chevalier T, Bonnay M, Couturas O, Fandi A, Armand JP: An ongoing phase I trial of Tomudex® (T) in combination with oxaliplatin (L-OHP) in advanced solid tumors: A promising and active combination. Ann Oncol 1998;9(suppl2):460.
83. Caponigro F, Casaretti R, McLeod HL, Budillon A, De Vita F, Avallone A, Cartine G, Gravina A, Barbarulo D, Morsman J, Fiore F, Catalane G, Comelia P, Comelia G: Phase I and pharmacokinetic study of Tomudex (TOM) + 5-fluorouracil (5-FU)/levofolinic acid (LFA) in advanced head and neck and colorectal cancer. Proc Am Assoc Clin Oncol 1998;17:909.
84. Rodriguez G, Villalona-Calero M, Schwartz G, Thurman A, Drengler R, Kraynak M, Johnston A, Clendeninn N, Von Hoff DD, Rowinsky E: A phase I and pharmacokinetic (PK) study of Thymitaq™ (AG337) in combination with cisplatin (CDDP) in patients (pts) with advanced solid tumors. Proc Am Assoc Clin Oncol 1998; 17:771.
85. Thoedtmann R, Kemmerich M, Dependbrock H, Blatter J, Ohnmacht U, Rastetter J, Hanauske A-R: A phase I study of MTA (multitargeted antifolate, LY231514) plus cisplatin (CIS) in patients with advanced solid tumors. Eur J Cancer 1997;33(suppl 8):S247.
86. De Gramont A, Figer A, Seymour M, Homerin M, Le Bail N, Cassidy J, Boni C, Cortes-Funes H, Freyer G, Hendler D, Luvet C: A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC). Proc Am Assoc Clin Oncol 1998;17:985.
87. Gamelin E, Meyer V, Delva R, Maillart P, Danquencin-Dorvall E, Lortholary A, Boisdorn M, Maigre M, Zampino MG, Cailleux PE, Brienza S, Krikorian A, Cvitkovic E, Larra F: Oxaliplatin and 5-fluorouracil synergism in pretreated advanced colorectal patients. Proc Am Assoc Clin Oncol 1997;16:1105.
88. Gerard B, Bleiberg H, Michel J, Finet C, Redoux P, Diana D, Dufrane JP, Vandaele D, Hendlisz A, Confente C, Malarme M, Michaux D, Brienza S: Oxaliplatin combined to 5-FU and folinic acid (5FU/FA) as second- or third-line treatment in patients with advanced colorectal cancer (CRC). Proc Am Assoc Clin Oncol 1997;16:1025.
89. Papamichael D, Joel SP, Seymour MT, Richards F, Bowerbank M, Slevin ML: Pharmacokinetic (PK) interaction between 5-fluorouracil (5-FU) and oxaliplatin (L-OHP). Proc Am Assoc Clin Oncol 1998;17:777.
90. Fizazi K, Soria JC, Bonnay M, Ruffie P, Ducreux M, le Chevalier T, Couturas O, Poterre M, Armand JP: Phase I/II dose-finding and pharmacokinetic (PK) study of 'Tomudex' (T) in combination with oxaliplatin (O) in advanced solid tumors. Proc Am Assoc Clin Oncol 1998;17:773.
91. Barone C, Pozzo C, Starkhammer H, Terzoli E, Dirix L, Humblet Y, Cognetti F, Gruia G, Cote C, Van Cutsem E: CPT-11 alternating with 5-fluorouracil (5FU)/folinic acid (FA): A multicentre phase II study in first-line chemotherapy (CT) of metastatic colorectal cancer (CRC). Preliminary results. Proc Am Assoc Clin Oncol 1997;16:957.
92. Rothenberg ML, Pazdur R, Rowinsky EK, Cohn AL, Alberts DS, Petit RG, Miller LL, Elfring GL, Murphy TC, Mayer RJ: A phase II multicenter trial of alternating cycles of irinotecan (CPT-11) and 5FU/LV patients with previously untreated metastatic colorectal cancer (CRC). Proc Am Assoc Clin Oncol 1997;16: 944.
93. Benhammouda A, Bastian G, Rixe O, Antoine E, Gozy M, Auclerc G, Grossin F, Nizri D, Gil-Delgado M, Weil M, Bismuth H, Mery Mignard D, Mahjoubi M, Lenseigne S, Khayat D: A phase I and pharmacokinetic (PK) study of CPT-11 (C) and 5-FU (F) combination. Proc Am Assoc Clin Oncol 1997;16:710.
94. Vanhoefer U, Harstrick A, Achterrath W, Kohne CH, Muller C, Kretschmar A, Krauss C, Wilke H, Seeber S: Phase I study of a weekly schedule of irinotecan (CPT-11), high dose folinic acid (FA) and 5-fluorouracil (5-FU) as first line chemotherapy (CT) in metastatic colorectal cancer Final results. Proc Am Assoc Clin Oncol 1998;17:779.
95. Levi F, Zidani R, Misset JL: Randomised multicenter trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997;350:681-686.
96. Spears SP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L, Danenberg PV: Thymidylate synthase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 1984;44: 4144-4150.
97. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989;7:890-899.
98. Peters GJ, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM: Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implication for treatment with fluorouracil, J Clin Oncol 1994;12:2035-2042.
99. Peters GJ, Van der Wilt CL, Van Groeningen CJ, Priest DG, Schmitz J, Smid K, Meijer S, Noordhuis P, Hoekman K, Pinedo HM: Effect of different leucovorin formulations on 5-fluorouracil induced thymidylate synthase inhibition in colon tumors and normal tissues from patients in relation to response to 5-fluorouracil; in Pfleiderer W, Rokos H (eds): Chemistry and Biology of Pteridines and Folates 1997: Proc 11th International Symposium. Berlin, Blackwell Science, pp 145-150.
100. Leichman L, Lenz H-J, Leichman CG, Groshen S, Danenberg KD, Baranda J, Spears CP, Boswell W, Silberman H, Ortega A, Stain S, Beart R, Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial. Eur J Cancer 1995;31:1306-1310.
101. Leichman CG, Danenberg PV, Tan M, Metzger R, Boswell W, Groshen S, Baranda J, Danenberg K, Leichman L, Lenz HJ: Quantitation of intratumoral thymidylate synthase expression predicts for disseminate colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223-3229.
102. Kornmann M, Danenberg PV, Berger HG, Danenberg KD, Safi F, Weindel M, Leder GH, Butzer U, Metzger R, Pillasch J, Lenz HJ, Link KH: Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 1997;16:29-35.
103. Johnston PG, Drake JC, Trepel J, Allegra CJ: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS-106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992;52: 4306-4312.
104. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Rene N, Milano G: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 1994; 10:1408-1411.
105. Van Triest B, Pinedo HM, Van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, Van der Wilt CL, Van Laar JAM, Jansen G, Peters GJ: Thymidylate synthase as main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors in 13 non-selected colon cancer cell lines. Clin Cancer Res 1999;5: 643-654.
106. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-2647.
107. Yamachika T, Nakanishi H, Inada K-I, Tsukamoto T, Kato T, Fukushima M, Inoue M, Tatematsu M: A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 1998; 82:70-77.
108. Lenz H-J, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Crookes P, Sliberman H, Baranda J, Garcia Y, Li J, Leichman L: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 1996;14: 176-182.
109. Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, Beckmann E, Weichselbaum RR, Allegra CJ, Vokes EE: Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 1997;89:308-313.
110. Pestalozzi BC, Johnston PG, Allegra CJ, Castiglione-Gertsch M, Rudenstam CM, Golouh R, Byrne MJ, Simmoncini E, Cortes-Funes H, Lindtner J, Trihia H, Gusterson BA, Goldhirsch A, Gelber RD, Peterson HF: Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 1997;15:1923-1931.
111. Saltz L, Danenberg K, Paty P, Kelsen D, Kemeny N, Salonga D, Park JM, Danenberg P: High thymidylate synthase (ts) expression does not preclude activity of CPT-11 in colorectal cancer (CRC). Proc Am Assoc Clin Oncol 1998;17:1080.
112. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F, Milano G: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase therapy. J Clin Oncol 1995;13:1663-1670.
113. Findlay MPN, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW: Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 1997;75:903-909.
114. Farrugia D, Cunningham D, Danenberg P, Danenberg K, Metzger R, Mitchell F, MacVicar D, McCarthy K, Aherne GW, Norman A, Jackman AL: A pharmacodynamic (PD) study of the thymidylate synthase (TS) inhibitor Tomudex in advanced colorectal cancer (CRC). Proc Am Assoc Cancer Res 1997;38: 4132.
115. Farrugia DC, Cunningham D, Mitchell F, Aheme GW, MacVicar D, McCarthy K, Norman AR, Jackman AL: A pharmacodynamic study of the antifolate thymidylate synthase inhibitor Tomudex™ in advanced colorectal cancer, in Pfleiderer W, Rokos H (eds): Chemistry and Biology of Pteridines and Folates 1997: Proc 11th International Symposium: Berlin, Blackwell Science, pp 241-244.
116. Zervos PH, Allen RH, Thornton DE, Thiem PA: Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514. Proc Am Assoc Clin Oncol 1997;16:907.
117. Lane DP: p53, guardian of the genome. Nature (Lond) 1992;358:15-16.
118. Kastan MB, Canman CE, Leonard CJ: p53, cell cycle control and apoptosis: Implications for cancer. Cancer Metastasis Rev 1995;14: 3-15.
119. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253:49-53.
120. Lenz HJ, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, Zhou L, Xiong YP, Danenberg PV, Leichman LP: p53 and thymidylate synthase (TS) expression in untreated stage II colon cancer: Association with recurrence, survival and tumor site. Clin Cancer Res 1998;4:1227-1234.
121. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP, Leichman CG: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival. Clin Cancer Res 1998; 4:1243-1250.
122. Elwell Y-P, Chang M, Leichman CG, Johnston PG, Groshen S, Leichman L, Beart RW, Lenz H-J: p53, p21 and thymidylate synthase (TS) protein expression: Associations with recurrence in stage II and III rectal cancer. Proc Am Assoc Clin Oncol 1997;16:915.
123. Ward SA, Joel SP, Papamichael D, Slevin ML, Glynne-Jones R: Thymidylate (TS) and p53 protein expression in patients with rectal cancer treated with pre-operative 5-fluorouracil (5-FU) based chemoradiotherapy (CRT). Proc Am Assoc Clin Oncol 1998;17:1040.
124. Seitz JF, Monges G, Milan C, Croue A, Diebold MD, Flejou JF, Piard F, Prevot S, Roignot P, Sabourin JC, Giovannini MH, Parriaux D: Thymidylate synthase (TS) and p53 expression predict for early event free survival (EFS) but not adjuvant chemotherapy efficacy in patients with colonic carcinoma (CC). Proc Am Assoc Clin Oncol 1998;17:1082.
125. Aschele C, Casazza S, Debernardis D, Guglielmi A, Caruso F, Sementa A, Lapertosa G, Nicolo G, Russa P, Parodi S, Sobrero A: Lack of correlation between p53 overexpression and response to FUra-based chemotherapy in advanced colorectal cancer patients. Proc Am Assoc Clin Oncol 1997;16:916.